Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy

Zhang, Yujie; Zhang, Yuxin; Zhang, Li

doi:10.1007/s00432-019-02840-3

Cited by 47 publications

(42 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these tumour samples, 20-30% exhibited MAGE-A4, NY-ESO-1 and/or SAGE expression. The MAGE-A, NY-ESO-1 and SAGE expression rates in this study were comparable to those reported previously [11,12,[21][22][23][24][25][26][27]. Among the 585 tumour samples, 214 oesophageal cancer samples were evaluable for the expression of all 3 CT antigens.…”

Section: Discussionsupporting

confidence: 89%

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

et al. 2020

View full text Add to dashboard Cite

Background: Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE). Methods: MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment. Results: In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was expressed in 28.6% of lung cancers, 25.3% of oesophageal cancers and 22.6% of ovarian cancers; and the SAGE antigen was expressed in 35.3% of prostate cancers, 32.9% of oesophageal cancers and 26.3% of ovarian cancers. The most common tumour type in this study was oesophageal cancer. MAGE-A4, NY-ESO-1 and SAGE antigen expression were assessed in 214 oesophageal cancer samples, among which 24 (11.2%) were triple-positive, 58 (27.1%) were positive for any two, 59 (27.6%) were positive for any one, and 73 (34.1%) were triple negative. Conclusions: Oesophageal cancer exhibited a relatively high rate of CT antigen mRNA expression positivity.

show abstract

Section: Discussionsupporting

confidence: 89%

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

et al. 2020

View full text Add to dashboard Cite

show abstract

“…comparable to those reported previously [11,12,[21][22][23][24][25][26][27]. Among the 585 tumour samples, 214 oesophageal cancer samples were evaluable for the expression of all 3 CT antigens.…”

Section: Eso-1 And/or Sage Expression the Mage-a Ny-eso-1 And Sagesupporting

confidence: 84%

MAGE-A4, NY-ESO-1 and SAGE expression rates and co-expression relationships in solid tumours

Ishihara

Kageyama

Miyahara

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE). Methods MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment. Results In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was expressed in 28.6% of lung cancers, 25.3% of oesophageal cancers and 22.6% of ovarian cancers; and the SAGE antigen was expressed in 35.3% of prostate cancers, 32.9% of oesophageal cancers and 26.3% of ovarian cancers. The most common tumour type was oesophageal cancer in this study. MAGE-A4, NY-ESO-1 and SAGE antigen expression were assessed in 214 oesophageal cancer samples, among which 24 (11.2%) were triple-positive, 58 (27.1%) were positive for any two, 59 (27.6%) were positive for any one, and 73 (34.1%) were triple-negative. Conclusions Oesophageal cancer exhibited a relatively high rate of CT antigen positivity. Our data indicate that oesophageal cancer is a promising candidate tumour for CT antigen-targeting immunotherapy and immune monitoring.

show abstract

“…Currently, overexpression of TTK was confirmed to occur in various cancers that harbor copy number gains (CNG) of chromosome 9p involving PD-L1. [ 33 ] Furthermore, TTK was overexpressed within the incredible lions share of esophageal squamous cell carcinoma tissues but barely expressed in ordinary tissues, [ 34 ] while another study demonstrated that high expression status of TTK corresponded positively with tumor grade and negatively with prognosis in glioblastoma. [ 35 ] Nowadays, there are few types of researches regarding the role of TTK in PCa.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy

Cited by 47 publications

References 92 publications

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

MAGE-A4, NY-ESO-1 and SAGE expression rates and co-expression relationships in solid tumours

Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis

Contact Info

Product

Resources

About